Abstract
The need for large quantities of purified plasmid DNA has increased as the applications of DNA vaccines continue to expand. This chapter describes a simple, scaleable procedure based on the fed-batch cultivation of various Escherichia coli clones, which can be easily implemented and scaled-up to large bioreactors. Although some clones may require minor modifications to the feeding strategy, in general, this procedure, implemented as described, is likely to support the production of milligram to gram quantities of plasmid DNA.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Chattergoon, M., Boyer, J., and Weiner, D. (1997) Genetic immunization: a new era in vaccines and immune therapeutics. FASEB 11, 753–763.
Restifo, N. and Rosenberg, S. (1999) Developing recombinant and synthetic vaccines for the treatment of melanoma. Curr. Opin. Oncol. 11, 50–57.
Shroff, K., Smith, L., Baine, Y., and Higgins, T. (1999) Potential for plasmid DNAs as vaccines for the new millenium. PSTT 2, 205–212.
Gurunathan, S., Wu, C., Friedag, B., and Seder, R. (2000) DNA vaccines: a key for inducing long-term cellular immunity. Curr. Opin. Immunol. 12, 442–447.
Gurunathan, S., Klinman, D., and Seder, R. (2000) DNA vaccines: immunology, application, and optimization. Annu. Rev. Immunol. 18, 927–974.
Mountain, A. (2000) Gene therapy: the first decade. TIBTECH 18, 119–128.
Robinson, H. (2000) DNA vaccines. Clin Microbiol News 23, 17–22.
Ferber, D. (2001) Gene therapy: safer and virus free. Science 294, 1638–1642.
Leitner, W. and Thalhamer, J. (2003) DNA vaccines for noninfectious diseases: new treatments for tumour and allergy. Expert Opin. Biol. Ther. 3, 627–638.
Bergmann-Leitner, E. S. and Leitner, W. W. (2004) Danger, death and DNA vaccines. Microbes Infect. 6, 319–327.
Berzofsky, J., Terabe, M., Oh, S., et al. (2004) Progress on new vaccine strategies for the immunotherapy and prevention of cancer. J. Clin. Invest. 113, 1515–1525.
Wang, S., Liu, X., Fisher, K., et al. (2000) Enhanced type I immune response to a hepatatis B DNA vaccine by formulation with calcium-or aluminium phosphate. Vaccine 18, 1227–1235.
Locher, C., Putnam, D., Langer, R., Witt, S., Ashlock, B., and Levy, J. (2003) Enhancement of a human immunodeficiency virus end DNA vaccine using a novel polycationic nanoparticle formulation. Immnunol. Lett. 90, 67–70.
Babiuk, S., Baca-Estrada, M., Foldvari, M., et al. (2004) Increased gene expression and inflamatory cell infiltration caused by electroporation are both important fro improving the efficacy of DNA vaccines. J. Biotechnol. 110, 1–10.
Powell, K. (2004) DNA vaccines-back in the saddle again? Nature Biotechnol. 22, 799–801.
Leitner, W., Ying, H., and Restifo, N. (2000) DNA and RNA-based vaccines: principles, progress and prospects. Vaccine 18, 765–777.
Prather, K. J., Sagar, S., Murphy, J., and Chartrain, M. (2003) Industrial scale production of plasmid DNA for vaccine and gene therapy: plasmid design, production, and purification. Enzyme Micro. Technol. 33, 865–883.
Riesenberg, D. (1991) High-cell density cultivation of Escherichia coli. Curr. Opin. Biotechnol. 2, 380–384.
Yee, L. and Blanch, H. (1992) Recombinant protein expression in high cell density fed-batch cultures of Escherichiae coli. Biotechnology 10, 1550–1556.
Lee, S. Y. (1996) High cell density culture of Escherichia coli. Trends Biotechnol. 14, 98–105.
Barouch, D. H., Craiu, A., Kuroda, M. J., et al. (2000) Augmentation of immune responses to HIV-1 and simian immunodeficiency virus DNA vaccines by IL-2/Ig plasmid administration in rhesus monkeys. Proc. Natl. Acad. Sci. USA 97, 4192–4197.
Barouch, D. H, Santra, S., Schmitz, J. E., et al. (2001) Control of verimia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science 290, 486–492.
Seo, J.-H. and Bailey, J. (1986) Continuous cultivation of recombinant Escherichiae coli: Existence of an optimum dilution rate for maximum plasmid and gene product concentration. Biotechnol. Bioeng. 28, 1590–1594.
Reinikainen, P., Korpela, K., Nissinen, V., et al. (1989) Escherichia coli production in fermentor. Biotechnol. Bioeng. 33, 386–393.
Reinikainen, P. and Virkajärvi, I. (1989) Escherichia coli growth and plasmid copy numbers in continuous cultivations. Biotechnol. Lett. 11, 222–230.
Namdev, P. K., Irwin, N., Thompson, B., and Gray, M. (1993) Effect of oxygen fluctuations on recombinant Escherichiae coli fermentation. Biotechnol. Bioeng. 41, 660–670.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2006 Humana Press Inc.
About this protocol
Cite this protocol
Listner, K., Bentley, L.K., Chartrain, M. (2006). A Simple Method for the Production of Plasmid DNA in Bioreactors. In: Saltzman, W.M., Shen, H., Brandsma, J.L. (eds) DNA Vaccines. Methods in Molecular Medicine™, vol 127. Humana Press. https://doi.org/10.1385/1-59745-168-1:295
Download citation
DOI: https://doi.org/10.1385/1-59745-168-1:295
Publisher Name: Humana Press
Print ISBN: 978-1-58829-484-5
Online ISBN: 978-1-59745-168-0
eBook Packages: Springer Protocols